City of Hope

City of Hope, a NCI-designated Comprehensive Cancer Center

Page Title

Skip Navigation

Global Navigation



Border Border
  
Click here to login to Secure Web Site   (authorized users only)  
  
Search results:  119  Clinical trial(s) found  (Page 1 of 5 )
Results per page: 25 50 100 All 1-25 Trials Jump to page:

The following studies are available for :
COH Protocol Number: 17345 ClinicalTrials.gov Number: NCT03199586

Principal Investigator: Vincent Chung, MD
Sponsor: Industrial

Title:  First-in-Human, Dose Finding, Open Label Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients with Advanced or Metastatic Solid Tumors (including Lymphoma)

COH Protocol Number: 17332

Principal Investigator: Vincent Chung, MD
Sponsor: Industrial

Title:  A Phase 1, Open-Label, Dose-Escalation, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects with Advanced Solid Tumors

COH Protocol Number: 17313 ClinicalTrials.gov Number: NCT02642965

Principal Investigator: Weili Sun, MD, PhD
Sponsor: Cooperative Group

Title:  COG AAML1421: A Phase 1/2 Study of CPX-351 (NSC# 775341) Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children with Relapsed Acute Myeloid Leukemia (AML)

COH Protocol Number: 17290 ClinicalTrials.gov Number: NCT03298516

Principal Investigator: Amandeep Salhotra, MD
Sponsor: Industrial

Title:  An Open-Label, Phase I, Dose-Escalation Study Evaluating the Safety and Tolerability of DCLL9718S in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Patients With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy

COH Protocol Number: 17228 ClinicalTrials.gov Number: NCT02675452

Principal Investigator: Anthony Stein, MD
Sponsor: Industrial

Title:  A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Acute Myeloid Leukemia

COH Protocol Number: 17227 ClinicalTrials.gov Number: NCT03224819

Principal Investigator: Anthony Stein, MD
Sponsor: Industrial

Title:  A Phase 1 First-In-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 673 Administered as Short Term Intravenous Infusions in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

COH Protocol Number: 17210 ClinicalTrials.gov Number: NCT02964013

Principal Investigator: Vincent Chung, MD
Sponsor: Industrial

Title:  A Phase 1 Trial of MK-7684 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

COH Protocol Number: 17209 ClinicalTrials.gov Number: NCT03275103

Principal Investigator: Amrita Krishnan, MD
Sponsor: Industrial

Title:  An Open-Label, Multicenter, Phase I Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of BFCR4350A in Patients with Relapsed or Refractory Multiple Myeloma

COH Protocol Number: 17179 ClinicalTrials.gov Number: NCT03267940

Principal Investigator: Vincent Chung, MD
Sponsor: Industrial

Title:  A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Hyaluronan-High (HA-high) Subjects with Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma

COH Protocol Number: 17168 ClinicalTrials.gov Number: NCT03255096

Principal Investigator: Alex Herrera, MD
Sponsor: Industrial

Title:  Open-Label, Dose Escalation/Expansion Phase 1B Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Combination of RO6870810 and Venetoclax, with or without Rituximab, in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

COH Protocol Number: 17151 ClinicalTrials.gov Number: NCT02335944

Principal Investigator: Karen Reckamp, MD
Sponsor: Industrial

Title:  A Phase IB/II, Multicenter, Open-label Study of EGF816 in Combination with INC280 in Adult Patients with EGFR Mutated Non-Small Cell Lung Cancer

COH Protocol Number: 17147 ClinicalTrials.gov Number: NCT02890329

Principal Investigator: Samer Khaled, MD
Sponsor: NCI Approved External Peer Review

Title:  PHI-95, NCI#10026: A Phase 1 Study of Ipilimumab in Combination with Decitabine in Relapsed or Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia

COH Protocol Number: 17146 ClinicalTrials.gov Number: NCT03113643

Principal Investigator: Anthony Stein, MD
Sponsor: Institutional

Title:  Phase 1 Study of SL-401 in Combination with Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia (AML) or in Treatment-Naive Subjects with AML Not Eligible for Standard Induction Therapy or in Subjects with High-Risk Myelodysplastic Syndrome (MDS)

COH Protocol Number: 17143 ClinicalTrials.gov Number: NCT03123783

Principal Investigator: Ravi Salgia, MD
Sponsor: Industrial

Title:  A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination with Nivolumab in Subjects with Non-small Cell Lung Cancer and Subjects with Metastatic Melanoma

COH Protocol Number: 17138 ClinicalTrials.gov Number: NCT03145181

Principal Investigator: Amrita Krishnan, MD
Sponsor: Industrial

Title:  A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64007957, a Humanized BCMA x CD3 DuoBody® Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma

COH Protocol Number: 17119 ClinicalTrials.gov Number: NCT01926587

Principal Investigator: Samer Khaled, MD
Sponsor: Industrial

Title:  Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib with Azacitidine in Patients with Myelodysplastic Syndrome or Acute Myeloid Leukemia

COH Protocol Number: 17109 ClinicalTrials.gov Number: NCT03104699

Principal Investigator: Edward Wang, MD
Sponsor: Industrial

Title:  A Phase 1 / 2, Open-Label, Multiple Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, With Expansion to Second-Line Cervical Cancer

COH Protocol Number: 17099 ClinicalTrials.gov Number: NCT02307149

Principal Investigator: Kim Margolin, MD
Sponsor: Industrial

Title:  A Phase Ib Study of Intratumoral Cavatak® (Coxsackievirus A21) and Ipilimumab in Patients with Advanced Melanoma

COH Protocol Number: 17095 ClinicalTrials.gov Number: NCT02539719

Principal Investigator: Mihaela Cristea, MD
Sponsor: Industrial

Title:  A Phase 1a/1b Dose Escalation and Expansion Study of Single-Agent SC-003 in Subjects with Platinum-Resistant/Refractory Ovarian Cancer

COH Protocol Number: 17084 ClinicalTrials.gov Number: NCT02052778

Principal Investigator: Daneng Li, MD
Sponsor: Industrial

Title:  A Dose-Finding Phase 1 Study of TAS-120 in Patients With Advanced Solid Tumors With or Without Fibroblast Growth Factor/Receptor (FGF/FGFR)-Related Abnormalities Followed By a Phase 2 Study in Patients With Advanced Solid Tumors or Multiple Myeloma With FGF/FGFR-Related Abnormalities

COH Protocol Number: 17080 ClinicalTrials.gov Number: NCT03150329

Principal Investigator: Alex Herrera, MD
Sponsor: Institutional

Title:  A Phase 1 Study of Pembrolizumab Plus Vorinostat for Relapsed or Refractory Diffuse Large B-cell Lymphoma, Follicular Lymphoma, and Hodgkin Lymphoma

COH Protocol Number: 17073 ClinicalTrials.gov Number: NCT03168061

Principal Investigator: Warren Chow, MD
Sponsor: Industrial

Title:  A Phase 1b/2 Dose-Escalation and Expansion Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft Tissue Sarcoma

COH Protocol Number: 17071 ClinicalTrials.gov Number: NCT02680184

Principal Investigator: Kim Margolin, MD
Sponsor: Industrial

Title:  A Multicenter, Two Part Open-Label, Phase 1B Clinical Study of CMP-001 Administered Either in Combination with Pembrolizumab or as Monotherapy in Subjects With Advanced Melanoma

COH Protocol Number: 17068 ClinicalTrials.gov Number: NCT03061201

Principal Investigator: Nadia Ewing, MD
Sponsor: Industrial

Title:  A Phase 1/2, Open-Label, Adaptive, Dose-Ranging Study to Assess the Safety and Tolerability of SB-525 (Recombinant AAV2/6 Human Factor 8 Gene Therapy) in Adult Subjects with Severe Hemophilia A

COH Protocol Number: 17066 ClinicalTrials.gov Number: NCT03145909

Principal Investigator: Joanne Mortimer, MD
Sponsor: Industrial

Title:  A Phase 1 Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects with Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)

 
Results per page: 25 50 100 All 1-25 Trials Jump to page:

 
 
  
NCI CCC LogoCity of Hope, An NCI-designated Comprehensive Cancer Center, is an innovative biomedical research, treatment and educational institution dedicated to the prevention and cure of cancer and other life-threatening illness.
Best Of logoCity of Hope has been named one of "America's Best Hospitals" in cancer and gynecology by U.S. News & World Report. Read more here...
NCI CCC LogoThe National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer.
Best Of logoWe subscribe to the HONcode of the Healthcare on the Net Foundation.